4D Molecular Therapeutics (FDMT) AI Stock Analysis

• Market Cap: $201.98M
• Dividend Yield: N/A
• Average Volume (3M): 477.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 227
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.86
• Shares Outstanding: 46,324,642
• 10 Day Avg. Volume: 539,250
• 30 Day Avg. Volume: 477,240
• PEG Ratio: -0.26
• Price to Book (P/B): -2.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.32
• Enterprise Value/Market Cap: 2.55
• Enterprise Value/Revenue: 25.43
• Enterprise Value/Gross Profit: 319.11
• Enterprise Value/Ebitda: -0.76
• 1Y Price Target: $29.40
• Price Target Upside: 574.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 48 Neutral
• Price Target: $4.50 ▲(3.21%Upside)

4D Molecular Therapeutics faces considerable financial and valuation challenges, reflected in its negative P/E ratio and cash flow issues. While technical indicators show short-term bullish momentum, the stock is overbought, suggesting a potential correction. The company's future hinges on successful research outcomes and maintaining external financing.

Positive Factors

Clinical Trials

The first patient was enrolled in North America in the FRONT-1 Ph3 clinical trial of 4D-150 in wet AMD, with over 50 clinical trial sites open to date.

Commercial Opportunity

Analyst is bullish on the commercial opportunity for 4D-150 due to its differentiated risk/benefit profile.

Financial Health

FDMT ended 4Q24 with $505.0mm in cash and equivalents, expected to fund operations, showcasing strong financial health.

Negative Factors

Funding Challenges

The recent charitable foundation funding gap impacting wAMD treatments and launch of biosimilars makes the analyst more conservative on the commercial opportunity for now.

Pricing Assumptions

The increase in the use of anti-VEGF biosimilars is expected to lower the average annual treatment cost for wAMD, leading to more conservative pricing assumptions for 4D-150.

Program Delays

4D-175, 4D-725, and 4D-310 remain paused pending additional financing or partnerships, indicating potential delays in these programs.

4D Molecular Therapeutics Business Overview & Revenue Model

Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

How the Company Makes Money

4D Molecular Therapeutics generates revenue primarily through strategic collaborations, licensing agreements, and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, research funding, milestone payments, and royalties based on the success and commercialization of the developed therapies. The company also invests in its own pipeline of gene therapy candidates, aiming to bring them to market, which could provide additional revenue streams through product sales. Furthermore, 4D Molecular Therapeutics may receive government grants and incentives for research and development in genetic therapies.

4D Molecular Therapeutics Financial Statement Overview

Summary

4D Molecular Therapeutics faces significant financial challenges typical of the biotechnology sector, particularly in early-stage development without consistent revenue streams. The balance sheet shows improvement, but the negative income and cash flow trends highlight ongoing operational hurdles. Future success will rely heavily on successful research outcomes and continued access to financing.

Income Statement

The company has experienced erratic revenue trends with significant fluctuations over the years. The lack of revenue in 2024 compared to the previous year denotes a challenging operational environment. Negative net income has been persistent, showcasing difficulties in achieving profitability. Margins are negative, and although the company had some revenue growth in prior years, sustainability remains questionable.

Balance Sheet

The company's balance sheet shows a strong equity base due to significant cash holdings, which is a positive aspect. However, the company's financial stability is undermined by negative equity in previous years. Recent improvements in stockholders' equity and low debt levels indicate improving financial health, but past fluctuations present a risk.

Cash Flow

Cash flow from operations is consistently negative, reflecting ongoing cash burn typical of early-stage biotech companies. While free cash flow remains negative, the increase in financing activities suggests reliance on external funding to sustain operations. Positive trends in financing cash flow are countered by high levels of capital expenditure.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
23.00K	37.00K	20.72M	3.13M	18.04M	13.61M
	Gross Profit
1.62M	37.00K	-76.37M	-751.00K	15.02M	-39.43M
	EBIT
-203.33M	-187.84M	-112.87M	-110.03M	-71.33M	-56.66M
	EBITDA
-203.17M	-187.84M	-107.12M	-106.15M	-68.31M	-55.22M
	Net Income Common Stockholders
-176.44M	-160.87M	-100.84M	-101.08M	-68.30M	-56.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
321.44M	424.88M	288.23M	218.64M	315.43M	276.73M
	Total Assets
515.73M	560.38M	339.89M	261.85M	353.49M	288.33M
	Total Debt
23.85M	24.61M	14.67M	16.12M	16.45M	0.00
	Net Debt
-109.67M	-124.73M	-234.44M	-202.52M	-298.98M	-276.73M
	Total Liabilities
46.01M	49.78M	32.06M	30.51M	560.48M	31.94M
	Stockholders Equity
469.72M	510.61M	307.83M	-314.49M	-207.00M	256.39M
Cash Flow		Free Cash Flow
-153.49M	-138.37M	-78.56M	-98.22M	-78.24M	-51.91M
	Operating Cash Flow
-153.25M	-134.59M	-75.79M	-86.69M	-69.13M	-50.91M
	Investing Cash Flow
-7.23M	-302.44M	115.72M	-17.05M	-172.68M	-1.00M
	Financing Cash Flow
18.42M	337.25M	156.83M	3.08M	118.09M	278.98M

4D Molecular Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 4.36 is above the 20-day moving average (MA) of 3.85, above the 50-day MA of 3.41, and below the 200-day MA of 6.58, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 64.22 is Neutral, neither overbought nor oversold. The STOCH value of 59.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.

4D Molecular Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	58 Neutral	$363.98M	―	123.38%	―	10.49%	47.31%
FATE	56 Neutral	$177.68M	―	-49.23%	―	105.85%	22.13%
SLN	56 Neutral	$243.24M	―	-99.23%	―	-40.10%	-16.60%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
RGLS	52 Neutral	$574.64M	―	-53.82%	―	―	44.85%
FDMT	48 Neutral	$201.98M	―	-32.97%	―	―	―
KRRO	45 Neutral	$148.84M	―	-60.22%	―	―	85.19%